| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
MURRIETA, Calif.—After recently increasing its investment in diagnostics company Zonda to 41%, CLX Investment Company, Inc., announced the signing of a letter of intent to acquire all remaining issued and outstanding Zonda shares. Zonda, which specializes in medical and non-medical tests using a proprietary enzyme detection system, is expected to launch its first product in the United States at the end of Q1 2008.
 
"We expect that the combination of Zonda's innovative testing products and strong, experienced leadership will allow the company to become a significant player in the diagnostic testing industry," says Steven R. Peacock, CLX consultant CEO. "For these reasons, we have targeted Zonda to become the focus of operations in CLX Investment Company."
 
One area of particular expertise for Zonda is point-of-care (POC) platforms, which according to a February 2006 report by BCC Research, will see its U.S. market almost double in value by 2010 to more than $9.5 billion. The same report suggests that the global POC market was just over $9 billion in 2005.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue